Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.28 CHF | +8.82% | +4.75% | +47.07% |
04-17 | Newron Pharmaceuticals Appoints Margarita Chavez as Independent Board Member | CI |
03-19 | Newron Pharmaceuticals S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 35.98M 38.47M 35.15M 3.08B | Sales 2025 * | 25.95M 27.75M 25.36M 2.22B | Capitalization | 139M 149M 136M 11.89B |
---|---|---|---|---|---|
Net income 2024 * | 13M 13.9M 12.7M 1.11B | Net income 2025 * | 4M 4.28M 3.91M 342M | EV / Sales 2024 * | 4.67 x |
Net Debt 2024 * | 29.11M 31.12M 28.44M 2.49B | Net Debt 2025 * | 2M 2.14M 1.95M 171M | EV / Sales 2025 * | 5.43 x |
P/E ratio 2024 * |
9.56
x | P/E ratio 2025 * |
32
x | Employees | 22 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.61% |
Latest transcript on Newron Pharmaceuticals S.p.A.
1 day | +8.82% | ||
1 week | +4.75% | ||
Current month | -6.19% | ||
1 month | -2.67% | ||
3 months | -11.86% | ||
6 months | +54.89% | ||
Current year | +47.07% |
Managers | Title | Age | Since |
---|---|---|---|
Stefan Weber
CEO | Chief Executive Officer | 60 | 14/05/12 |
Luca Benatti
FOU | Founder | 63 | 31/12/97 |
Roberto Galli
DFI | Director of Finance/CFO | - | 31/12/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 31/12/07 | |
Luca Benatti
FOU | Founder | 63 | 31/12/97 |
Ulrich Köstlin
CHM | Chairman | 71 | 31/12/12 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 7.28 | +8.82% | 59,318 |
25/04/24 | 6.69 | -4.43% | 63,462 |
24/04/24 | 7 | 0.00% | 43,337 |
23/04/24 | 7 | -2.51% | 32,096 |
22/04/24 | 7.18 | +3.31% | 62,322 |
Delayed Quote Swiss Exchange, April 26, 2024 at 04:31 pm
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+47.07% | 148M | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.35B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- NWRN Stock